Found 8 matching trials
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
PHASE3This is a Phase 3, multicenter, randomized, double-blind, placebo-controlle...
Location
Allakos Investigational Site
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
PHASE3This is a Phase 3, multi-center, randomized, double-blind, placebo-controll...
Location
Allakos Investigational Site
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
PHASE2This is a Phase 2/3, multi-center, randomized, double-blind, placebo-contro...
Location
Allakos Investigational Site
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
PHASE2This is a Phase 2, multicenter, randomized, double-blind, placebo-controlle...
Location
Allakos Investigational Site 227-024
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
PHASE3This is a Phase 3, open-label, extension study to assess the long term effi...
Location
Allakos Investigational Site 216-068
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
PHASE2This is a Phase 2, multicenter, randomized, double-blind, placebo-controlle...
Location
Allakos Investigational Site 218-034
A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers
PHASE1This is a Phase 1, single-center study to evaluate safety, tolerability, an...
Location
Allakos Investigational Site
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
PHASE3This is a Phase 3, multi-center, randomized, double-blind, placebo-controll...
Location
Allakos Investigational Site